Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects (good and bad) secukinumab has
on the subject and their pyoderma gangrenosum.
Secukinumab is a type of medicine called human monoclonal antibodies. Monoclonal antibodies
are proteins that recognize and attach to other specific proteins (in this case, immune
system hormones called "cytokines") that your body produces. The cytokine (a "messenger"
protein in the body) that secukinumab binds to and reduces the activity of is a naturally
occurring cytokine called interleukin-17A (IL-17A). IL-17A is believed to be partly
responsible for inflammation (pain, swelling, redness), and researchers believe that IL-17A
may cause symptoms PG.